Free Trial
NASDAQ:GLUE

Monte Rosa Therapeutics (GLUE) Stock Price, News & Analysis

Monte Rosa Therapeutics logo
$5.08 +0.11 (+2.11%)
As of 11:42 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

About Monte Rosa Therapeutics Stock (NASDAQ:GLUE)

Key Stats

Today's Range
$4.94
$5.12
50-Day Range
$3.70
$5.08
52-Week Range
$3.50
$12.40
Volume
137,816 shs
Average Volume
1.08 million shs
Market Capitalization
$312.16 million
P/E Ratio
63.45
Dividend Yield
N/A
Price Target
$15.33
Consensus Rating
Moderate Buy

Company Overview

Monte Rosa Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
27th Percentile Overall Score

GLUE MarketRank™: 

Monte Rosa Therapeutics scored higher than 27% of companies evaluated by MarketBeat, and ranked 797th out of 922 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Monte Rosa Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on 2 buy ratings, 1 hold rating, and no sell ratings.

  • Amount of Analyst Coverage

    Monte Rosa Therapeutics has received no research coverage in the past 90 days.

  • Read more about Monte Rosa Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for Monte Rosa Therapeutics are expected to grow in the coming year, from ($1.49) to ($1.41) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Monte Rosa Therapeutics is 63.45, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 25.96.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Monte Rosa Therapeutics is 63.45, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 27.17.

  • Price to Book Value per Share Ratio

    Monte Rosa Therapeutics has a P/B Ratio of 1.40. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Read more about Monte Rosa Therapeutics' valuation and earnings.
  • Percentage of Shares Shorted

    19.29% of the float of Monte Rosa Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Monte Rosa Therapeutics has a short interest ratio ("days to cover") of 15, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Monte Rosa Therapeutics has recently increased by 9.78%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Monte Rosa Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Monte Rosa Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    19.29% of the float of Monte Rosa Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Monte Rosa Therapeutics has a short interest ratio ("days to cover") of 15, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Monte Rosa Therapeutics has recently increased by 9.78%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    Monte Rosa Therapeutics has a news sentiment score of -0.46. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.57 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 1 news article for Monte Rosa Therapeutics this week, compared to 2 articles on an average week.
  • Insider Buying vs. Insider Selling

    In the past three months, Monte Rosa Therapeutics insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 6.50% of the stock of Monte Rosa Therapeutics is held by insiders.

  • Percentage Held by Institutions

    79.96% of the stock of Monte Rosa Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Monte Rosa Therapeutics' insider trading history.
Receive GLUE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Monte Rosa Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

GLUE Stock News Headlines

Market Panic: Trump Just Dropped a Bomb on Your Stocks
tock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tariffs just lit the fuse. Millions of investors are blindsided as stocks plunge… but this is only Phase 1. If you're still holding the wrong assets, you could lose 30% or more in the coming weeks.
Monte Rosa Therapeutics Insider Ups Holding During Year
Monte Rosa Therapeutics: Exercise Extreme Caution
See More Headlines

GLUE Stock Analysis - Frequently Asked Questions

Monte Rosa Therapeutics' stock was trading at $6.94 at the beginning of 2025. Since then, GLUE stock has decreased by 26.9% and is now trading at $5.0750.

Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) released its earnings results on Thursday, May, 8th. The company reported $0.57 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.24) by $0.81. The business had revenue of $84.93 million for the quarter, compared to analyst estimates of $13.57 million. Monte Rosa Therapeutics had a net margin of 3.86% and a trailing twelve-month return on equity of 2.65%.

Monte Rosa Therapeutics (GLUE) raised $211 million in an initial public offering (IPO) on Thursday, June 24th 2021. The company issued 11,700,000 shares at $17.00-$19.00 per share.

Shares of GLUE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Monte Rosa Therapeutics investors own include AU Optronics (AUOTY), Waste Connections (WCN), American Water Works (AWK), The RMR Group (RMR), DiamondRock Hospitality (DRH), iShares Micro-Cap ETF (IWC) and Triple Flag Precious Metals (TFPM).

Company Calendar

Last Earnings
5/08/2025
Today
7/08/2025
Next Earnings (Estimated)
8/14/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:GLUE
Fax
N/A
Employees
90
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$15.33
High Stock Price Target
$19.00
Low Stock Price Target
$10.00
Potential Upside/Downside
+208.5%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.67
Research Coverage
3 Analysts

Profitability

Trailing P/E Ratio
62.13
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$72.70 million
Pretax Margin
5.93%

Debt

Sales & Book Value

Annual Sales
$75.62 million
Price / Cash Flow
N/A
Book Value
$3.63 per share
Price / Book
1.37

Miscellaneous

Free Float
57,512,000
Market Cap
$305.70 million
Optionable
Optionable
Beta
1.41
Ten Starter Stocks For Beginners to Buy Now Cover

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

This page (NASDAQ:GLUE) was last updated on 7/8/2025 by MarketBeat.com Staff
From Our Partners